Patent ductus arteriosus (PDA) in the preterm infant – management
Haemodynamically significant PDA · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A persistent ductus arteriosus in preterm infants can cause a large left-to-right shunt with pulmonary over-circulation and systemic steal, contributing to respiratory deterioration, heart failure, NEC, IVH and renal hypoperfusion. Management ranges from conservative/supportive care through targeted pharmacological closure to catheter/surgical closure for a haemodynamically significant PDA.
Red flags
- Worsening respiratory failure or heart failure attributable to the shunt
- Pulmonary haemorrhage
- Associated NEC or feed intolerance
- Oliguria/rising creatinine during COX-inhibitor treatment
- Signs of a ductal-dependent lesion (do not close if duct-dependent circulation suspected)
Assessment
Differential diagnosis
- Worsening respiratory distress syndrome or evolving BPD
- Sepsis with hyperdynamic circulation
- Other congenital heart disease (e.g. aortopulmonary window, VSD)
- Anaemia-related high-output state
- Pulmonary over-circulation from fluid overload
- Pulmonary hypertension with ductal shunting
Investigations
- Echocardiography to assess ductal size, shunt direction and volume and cardiac loading
- Chest radiograph (cardiomegaly, pulmonary plethora)
- Clinical assessment (murmur, bounding pulses, wide pulse pressure, active precordium)
- Blood gas and respiratory support trend
- Renal function and urine output
- Platelet count and renal function before/ during medical closure
Management
- Assess haemodynamic significance clinically and by echo (duct diameter, La:Ao ratio, diastolic flow reversal, left heart dilation).
- Start with supportive/conservative measures: judicious fluid restriction, maintain adequate haematocrit, and optimise respiratory support with adequate PEEP.
- Avoid routine prophylactic treatment of all ducts; reserve active treatment for a haemodynamically significant PDA causing morbidity.
- For significant PDA, offer pharmacological closure with a COX inhibitor (ibuprofen or indometacin) or paracetamol, after checking contraindications.
- Check platelets, renal function and exclude active bleeding/NEC/significant renal impairment before COX inhibitors.
- Monitor renal function, urine output, platelets and for GI bleeding during and after a treatment course.
- Reassess with echocardiography after the course; consider a second course if still significant and medically appropriate.
- Refer for catheter (transcatheter device) closure or surgical ligation if medical treatment fails/contraindicated and the PDA remains haemodynamically significant.
- Continue to optimise ventilation, nutrition and fluid balance throughout.
- Monitor for and manage complications such as pulmonary haemorrhage and heart failure.
- Document indications and shared decision-making given uncertainty about optimal timing.
- Plan post-closure echo and clinical surveillance.
Drugs & doses
Ibuprofen IV 10 mg/kg then 5 mg/kg at 24 and 48 h (first course)
Indometacin IV 0.2 mg/kg then 0.1–0.2 mg/kg every 12–24 h for 2 further doses
Paracetamol (IV/PO) 15 mg/kg every 6 h for 3–7 days as an alternative where COX inhibitors contraindicated
Furosemide avoid routinely during indometacin; use 1 mg/kg IV only for clear fluid overload
Disposition
NICU with echocardiography and neonatal cardiology access; refer to a cardiac centre for transcatheter or surgical closure when medical therapy fails or is contraindicated.
Complications & pitfalls
- Pulmonary over-circulation and haemorrhage
- Heart failure and failure to wean from ventilation
- NEC and feeding intolerance
- Acute kidney injury or GI bleeding from COX inhibitors
- Post-ligation cardiac syndrome after surgery
- Chronic lung disease
Exam pearls
- Treat the baby, not just the echo – reserve active closure for a genuinely haemodynamically significant PDA.
- Always exclude a duct-dependent lesion before attempting closure.
- Paracetamol is a useful alternative when COX inhibitors are contraindicated.
- Many small ducts close spontaneously with conservative management.
- Watch renal function, platelets and GI signs closely during COX-inhibitor courses.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.